Schnaidt M, Wernet D, Mayer G, Northoff H
Abteilung für Transfusionsmedizin mit Blutbank, Universität Tübingen, Deutschland.
Beitr Infusionsther Transfusionsmed. 1994;32:240-3.
Alloimmunization to the platelet-specific antigen systems HPA-1, -3 and -5 was studied in 59 multitransfused patients (31 females, 16 males, 12 children) with haematologic-oncologic disorders. All patients tested had broad-reacting or multispecific HLA antibodies. Of these, 10 (17%) were found to have additional platelet-specific alloantibodies. With respect to HLA sensitization, 9 out of 10 platelet-specific alloantibodies were found in sera which showed HLA antibodies reacting with more than 95% of unselected panel cells. Determination of antibody specificity revealed 6 patients with anti-HPA-1b, one patient with anti-HPA-3a, and 2 patients with anti-HPA-1b combined with anti-HPA-3a. One patient had anti-HPA-5b; in retrospect, only the HPA-5b antibody was demonstrable before the beginning of transfusion therapy and before HLA sensitization.
对59例患有血液肿瘤疾病的多次输血患者（31名女性、16名男性、12名儿童）进行了针对血小板特异性抗原系统HPA-1、-3和-5的同种免疫研究。所有检测的患者均有广泛反应性或多特异性HLA抗体。其中，10例（17%）被发现有额外的血小板特异性同种抗体。关于HLA致敏情况，在显示HLA抗体与超过95%未选择的细胞板细胞发生反应的血清中发现了10例血小板特异性同种抗体中的9例。抗体特异性测定显示，6例患者有抗-HPA-1b，1例患者有抗-HPA-3a，2例患者有抗-HPA-1b合并抗-HPA-3a。1例患者有抗-HPA-5b；回顾发现，仅在输血治疗开始前且在HLA致敏前可检测到HPA-5b抗体。
